- Merck & Co. (New York, NY)
- …research (beyond that obtained in the terminal degree program) in the Cardiovascular & Pulmonary therapeutic areas and demonstrated scientific excellence in the ... - Maintaining new and updated trends and new information in the Cardiovascular & Pulmonary/translational science areas Network and partner with important external… more
- Cipla (Hauppauge, NY)
- …with focus on a range of therapeutic areas, including cardiovascular , anti-infective, CNS, anti-inflammatory, anti-diabetic, and anti-depressants. The company was ... founded in 2003 and is based in Central Islip and Hauppauge, New York. In October 2020, InvaGen established its project site in Fall River, Massachusetts to support the launch of Cipla's respiratory business in the United States. Equal Opportunity Employer… more
- Cipla (Hauppauge, NY)
- …with focus on a range of therapeutic areas, including cardiovascular , anti-infective, CNS, anti-inflammatory, anti-diabetic, and anti-depressants. The company was ... founded in 2003 and is based in Central Islip and Hauppauge, New York. In October 2020, InvaGen established its project site in Fall River, Massachusetts to support the launch of Cipla's respiratory business in the United States. Equal Opportunity Employer… more
- Cipla (Hauppauge, NY)
- …with focus on a range of therapeutic areas, including cardiovascular , anti-infective, CNS, anti-inflammatory, anti-diabetic, and anti-depressants. The company was ... founded in 2003 and is based in Central Islip and Hauppauge, New York. In October 2020, InvaGen established its project site in Fall River, Massachusetts to support the launch of Cipla's respiratory business in the United States. Equal Opportunity Employer… more
- Cipla (Central Islip, NY)
- …with focus on a range of therapeutic areas, including cardiovascular , anti-infective, CNS, anti-inflammatory, anti-diabetic, and anti-depressants. The company was ... founded in 2003 and is based in Central Islip and Hauppauge, New York. In October 2020, InvaGen established its project site in Fall River, Massachusetts to support the launch of Cipla's respiratory business in the United States. Equal Opportunity Employer… more
- Cipla (Hauppauge, NY)
- …with focus on a range of therapeutic areas, including cardiovascular , anti-infective, CNS, anti-inflammatory, anti-diabetic, and anti-depressants. The company was ... founded in 2003 and is based in Central Islip and Hauppauge, New York. In October 2020, InvaGen established its project site in Fall River, Massachusetts to support the launch of Cipla's respiratory business in the United States. Equal Opportunity Employer… more
- Cipla (Hauppauge, NY)
- …with focus on a range of therapeutic areas, including cardiovascular , anti-infective, CNS, anti-inflammatory, anti-diabetic, and anti-depressants. The company was ... founded in 2003 and is based in Central Islip and Hauppauge, New York. As of February 18, 2016, InvaGen Pharmaceuticals, Inc. operates as a subsidiary of Cipla (EU) Limited.EEO Statement Cipla is an Equal Opportunity Employer. All qualified applicants will… more
- Novo Nordisk Inc. (Buffalo, NY)
- …conditions such as diabetes, obesity, and the reduction of major adverse cardiovascular events. Our ambition is to advance broad cardiometabolic disease management ... by bringing exciting new therapies to market to improve patient outcomes. As a team member, you will connect therapies to new specialties, build cardiometabolic advocates, and apply learnings that impact local markets and the organization in a… more
- Cipla (Hauppauge, NY)
- …with focus on a range of therapeutic areas, including cardiovascular , anti-infective, CNS, anti-inflammatory, anti-diabetic, and anti-depressants. The company was ... founded in 2003 and is based in Central Islip and Hauppauge, New York. As of February 18, 2016, InvaGen Pharmaceuticals, Inc. operates as a subsidiary of Cipla (EU) Limited. more
- Daiichi Sankyo, Inc. (New York, NY)
- …to help people. In addition to a strong portfolio of medicines for cardiovascular diseases, under the Group's 2025 Vision to become a "Global Pharma Innovator ... with Competitive Advantage in Oncology," Daiichi Sankyo is primarily focused on providing novel therapies in oncology, as well as other research areas centered around rare diseases and immune disorders. Summary: The Oncology Territory Manager represents… more
